there were better ways to target medicines precisely where they are needed? At Innocoll, our collagen-matrix technology is designed to transform today's medicines to help create a healthier tomorrow.


Given the negative side effects and costs associated with opioid use, there is increasing focus from hospitals, payors, and regulators on treatments that reduce opioid use in the treatment of postsurgical pain.

XARACOLL, bupivacaine HCl collagen-matrix implant, utilizes our proprietary collagen-based delivery technology and has been studied in two Phase III clinical trials for postsurgical analgesia as part of multi-modal therapy for patients undergoing hernia repair.

XARACOLL has been studied to deliver the anesthetic directly at the surgical site and to reduce pain and opioid use after surgery.

Business Development Group
Unit 9, Block D
Monksland Business Park
Co. Roscommon
Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: businessdevelopment@innocoll.com

Innocoll Engineering Better Medicines logo and other brands are trademarks of Innocoll Pharmaceuticals. © 2016. Innocoll Holdings plc, is registered in Ireland as a public limited company with registration number 544604 and has its registered office at Unit 9, Block D, Monksland Business Park, Monksland, Athlone, Co. Roscommon, Ireland.